ERBB2 and breast cancer: In HR+/HER2+ breast cancer cell lines, ER signaling and ER transcriptional activity are upregulated following treatment with HER2-targeted agents trastuzumab and lapatinib and ER functions as the key survival pathway reducing sensitivity to HER2-blockade [13, 15, 16].